Multiple Myeloma Support + Trials

ABBV-383 is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BCMA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells. When CD3 is engaged on a T cell, it turns the T-cell on and makes it kill whatever cell triggered the activation. Because ABBV-383 sticks very strongly to the BCMA on your myeloma cells, nearby T-cells should specifically attack your tumor cells.

This study is open-label, meaning that everyone on the study will receive ABBV-383. It is a Phase 1, First-in-Human trial, meaning that it is the first study where ABBV-383 will be given to human patients. ABBV-383 is an investigational agent, meaning that it is still being tested for safety and efficacy and has not yet been approved by the FDA.

The purpose of the Study is:

To find the highest dose of ABBV-383 that can be given without causing severe side effects.
To find out the side effects seen when giving ABBV-383 at different doses.
To gather early information about how well ABBV-383 treats myeloma.
To measure the amount of ABBV-383 in the blood at different doses.
To evaluate biomarkers in your blood or at relevant disease site(s). A biomarker is a substance in your blood or at relevant disease site(s) that may indicate how your disease is progressing or how effective a certain treatment is.

SparkCures ID	998
Trial Phase	Phase 1
Enrollment	133 Patients
Treatments	ABBV-383
Tags	B-Cell Maturation Antigen (BCMA) Bispecific Antibody CD3
Trial Sponsors	Teneobio Inc.
Trial Collaborators	AbbVie
NCT Identifier	NCT03933735

A Multi-center, Phase 1, Open-label, Dose-escalation and Expansion Study of ABBV-383

Overview

Am I Eligible?

US Trial Locations

Trial Links

First Patient Dosed in Phase 1 Trial of Antibody for Advanced Multiple Myeloma, Teneobio Announces